{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:14:33Z","timestamp":1789913673815,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,5,27]],"date-time":"2018-05-27T00:00:00Z","timestamp":1527379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00277-018-3365-y","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T19:01:13Z","timestamp":1527361273000},"page":"1591-1600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial"],"prefix":"10.1007","volume":"97","author":[{"given":"Martin","family":"Griesshammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Egyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Callum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Sivgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bensasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmudul","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Perez","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,27]]},"reference":[{"issue":"5","key":"3365_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937\u2013951. \n                    https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"issue":"9","key":"3365_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881. \n                    https:\/\/doi.org\/10.1038\/leu.2013.163","journal-title":"Leukemia"},{"issue":"2","key":"3365_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","volume":"34","author":"H Geyer","year":"2016","unstructured":"Geyer H, Scherber R, Kosiorek H et al (2016) Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol 34(2):151\u2013159. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.62.9337","journal-title":"J Clin Oncol"},{"issue":"10","key":"3365_CR4","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"issue":"7","key":"3365_CR5","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","volume":"111","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, Rumi E, Caramella M et al (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383\u20133387. \n                    https:\/\/doi.org\/10.1182\/blood-2007-11-121434","journal-title":"Blood"},{"issue":"10","key":"3365_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755\u2013761. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2004.06.032","journal-title":"Am J Med"},{"issue":"6","key":"3365_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.31.8436","journal-title":"J Clin Oncol"},{"issue":"1","key":"3365_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"issue":"6","key":"3365_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","volume":"58","author":"RM Scherber","year":"2017","unstructured":"Scherber RM, Geyer HL, Dueck AC et al (2017) The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma 58(6):1481\u20131487. \n                    https:\/\/doi.org\/10.1080\/10428194.2016.1246733","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3365_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larran","year":"2016","unstructured":"Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC et al (2016) Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172(5):786\u2013793. \n                    https:\/\/doi.org\/10.1111\/bjh.13886","journal-title":"Br J Haematol"},{"issue":"6","key":"3365_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran A, Pereira A, Cervantes F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363\u20131369. \n                    https:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"issue":"5","key":"3365_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11899-016-0311-8","volume":"11","author":"A Reiter","year":"2016","unstructured":"Reiter A, Harrison C (2016) How we identify and manage patients with inadequately controlled polycythemia vera. Curr Hematol Malig Rep 11(5):356\u2013367. \n                    https:\/\/doi.org\/10.1007\/s11899-016-0311-8","journal-title":"Curr Hematol Malig Rep"},{"issue":"17","key":"3365_CR13","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(17):1670\u20131671. \n                    https:\/\/doi.org\/10.1056\/NEJMc1502524","journal-title":"N Engl J Med"},{"issue":"7","key":"3365_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, Vannucchi AM, Griesshammer M et al (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101(7):821\u2013829. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.143644","journal-title":"Haematologica"},{"key":"3365_CR15","unstructured":"JAKAFI\u00ae (ruxolitinib) [package insert]. Wilmington DICD"},{"key":"3365_CR16","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2014-07-551929","volume":"124","author":"AM Vannucchi","year":"2014","unstructured":"Vannucchi AM, Verstovsek S, Jones MM et al (2014) Efficacy of ruxolitinib by baseline spleen volume in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Blood 124:1840 (abstract)","journal-title":"Blood"},{"issue":"1","key":"3365_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Griesshammer M, Palandri F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30558-7","journal-title":"Lancet Oncol"},{"issue":"23","key":"3365_CR18","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G et al (2013) Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 121(23):4778\u20134781. \n                    https:\/\/doi.org\/10.1182\/blood-2013-01-478891","journal-title":"Blood"},{"issue":"22","key":"3365_CR19","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL (2017) Myeloproliferative neoplasms. N Engl J Med 376(22):2168\u20132181. \n                    https:\/\/doi.org\/10.1056\/NEJMra1406186","journal-title":"N Engl J Med"},{"issue":"1","key":"3365_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3324\/haematol.2015.129155","volume":"102","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM (2017) From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica 102(1):18\u201329. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.129155","journal-title":"Haematologica"},{"key":"3365_CR21","volume-title":"Hematologica 102 ([Abstract: P705])","author":"N Polverelli","year":"2017","unstructured":"Polverelli N, Binotto G, Palumbo GA et al (2017) Epidemiology, outcome and risk factors for infectious complications in mf patients receiving ruxolitinib. A multicenter study on 373 patients. In: Hematologica 102 ([Abstract: P705])"},{"issue":"5","key":"3365_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E, Guglielmelli P, Pieri L et al (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol 87(5):552\u2013554. \n                    https:\/\/doi.org\/10.1002\/ajh.23160","journal-title":"Am J Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3365-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T19:05:34Z","timestamp":1558897534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,27]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3365"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3365-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,27]]},"assertion":[{"value":"30 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the central ethics committee or institutional review board at each participating institution and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MG has participated in speakers bureaus and received honoraria from Novartis, Shire, and AOP Orphan. FPas has participated in speakers bureaus and advisory boards for Novartis and has received honoraria from Novartis. TD has received consultancy fees from Gilead, Novartis, and Janssen and has participated in advisory boards for Novartis, Gilead, and Janssen. JC has received research support for speaking for Novartis at hematology rounds. AMV has received research funding and participated in advisory boards for Novartis and has participated in speakers bureaus for Novartis and Shire. JPR, CB, and MK are employees of Novartis. GS has participated in speakers bureaus for Novartis, has received research funding and honoraria from Novartis, and has received honoraria from Celgene, Bristol-Myers Squibb, and Gilead. Fpal has received honoraria from Novartis. ME, PG, SS, and GB have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}